Actively Recruiting
Phase II Study of Cryoablation Combined With Camrelizumab for Advanced or Unresectable Soft Tissue Sarcoma After Standard Treatment Failure
Led by Sun Yat-sen University · Updated on 2026-05-22
57
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of cryoablation and the PD-1 antibody camrelizumab for patients with advanced or inoperable soft tissue sarcomas who have not responded to standard treatments. Soft tissue sarcomas are rare malignant tumors with poor prognosis and limited treatment options, especially in advanced stages. This phase II trial aims to assess the effectiveness and safety of this combined approach as a potential new treatment. Participants will receive local cryoablation on selected tumor lesions every three weeks along with camrelizumab therapy. One to three lesions per patient are treated locally, while at least two lesions are observed without direct treatment. Patients may undergo six to eight cycles of this combined treatment. If the disease remains stable or improves, camrelizumab may be continued until disease progression or side effects occur. During the study, tumor responses are monitored every six weeks using imaging scans following RECIST 1.1 criteria. Patients undergo baseline evaluations for all lesions and regular laboratory and heart function tests to ensure safety. The primary outcome measured is the overall response rate to treatment, with secondary outcomes including overall survival. Participants are expected to visit the research center regularly for assessments and treatment over the study period.
CONDITIONS
Brief Title
Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma
Research Team
X
Xing Zhang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here